13 known cases. View patent page →
IPR challenging claims 1-6 of the '405 patent. The PTAB instituted review and issued a Final Written Decision holding all claims not shown unpatentable; IPR certificate issued 2020-02-10.
IPR challenging the '405 patent was instituted and joined into lead IPR2017-00854; final written decision issued and latest docket activity was 2018-08.
IPR filed by Sun Pharmaceutical Industries challenging the '405 patent; joined with IPR2017-00854 and finalized by written decision.
IPR by Actavis Elizabeth and Teva challenging the '405 patent was joined with IPR2017-00854 and terminated with the Final Written Decision on 2018-07-11.
Reported appeal from the PTAB Final Written Decision in IPR2017-00854 and joined cases; reported as dismissed. Individual disposition not independently verified.
Appeal from D. Del. 1:18-cv-01043. The Federal Circuit first affirmed validity and infringement on January 3, 2022, then on rehearing vacated and reversed, holding the '405 patent claims invalid for lack of written description (38 F.4th 1013). Rehearing en banc was denied and mandate issued approximately October 18, 2022.
Petition for certiorari from the Federal Circuit's invalidation of the '405 patent; emergency stay of mandate was granted by Chief Justice Roberts on 2022-09-29; certiorari was denied (143 S. Ct. 1748).
ANDA/Hatch-Waxman suit against Apotex asserting the '405 patent; resolved by confidential settlement licensing entry before patent expiry.
ANDA suit against Teva (ANDA No. 208008) asserting the '405 patent; filed around 2018-07-16 and settled.
ANDA suit against Sun Pharma entities asserting the '405 patent; filed around 2018-07-16 and settled.
ANDA suit against Mylan (ANDA No. 208005) asserting the '405 patent; settled with proposed consent judgment and injunction filed 2020-10-26; later dispute over post-CAFC launch led to TRO entered 2022-10-11.
Suit against Handa entities asserting the '405 patent and also US 10,543,179. Handa sought summary judgment on the '405 patent after the Federal Circuit's June 2022 invalidation; final disposition not verified.
Suit against Handa Pharmaceuticals asserting the '405 patent; details and outcome not verified from the narrative.